RXQ Compounding Recalls Ketamine Injection Due to Sterility Concerns
RXQ Compounding LLC is recalling Ketamine 50 mg/mL injection solution because the product lacks assurance of sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of assurance of sterility in an injectable drug, which poses a significant risk of serious injury or death from infection.
Plain-English summary
RXQ Compounding LLC is recalling Ketamine 50 mg/mL (NPV) Injection Solution (C-III), 10 mL per vial, NDC 70731-0173-10. The recall was initiated because the product lacks assurance of sterility.
The affected product was distributed nationwide in the United States. All lots within the expiry date are included in this recall.
Consumers and healthcare providers should stop using the recalled product and contact their pharmacist or the recalling firm for further instructions.
The recalled product
- Product
- KETAMINE 50 MG/ML (NPV) INJECTION SOLUTION (C-III), 10 ML per vial, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0173-10
- Manufacturer
- RXQ Compounding LLC
- Category
- Drug — Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 86 recalled by RXQ Compounding LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · RXQ Compounding LLC
See all →- HighRXQ Compounding Recalls Niacinamide Vials Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereRXQ Compounding Recalls Glutathione Injection Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereFDA Recalls Fentanyl Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2019-08-14
- SevereRXQ Compounding Recalls Methylcobalamin Injectable Solution Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereRXQ Compounding Recalls Folic Acid Injection Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
Same hazard · infection
See all →- SevereSafeguard US Operating LLC Recalls Compression Bandages Due to Degradation
FDA (Devices) · 2026-10-14
- SevereStryker Bard EP XT Decapolar Steerable Diagnostic EP Catheter Recalled for Sterile Barrier Breach
FDA (Devices) · 2026-10-14
- HighEmbosphere Microspheres Recalled Due to Packaging Sterility Concerns
FDA (Devices) · 2026-10-07
- SevereAurolab Trust Recalls FOCUS PI Eye Drops Due to Sterility Concerns
FDA (Drugs) · 2026-10-07
- HighFDA Recalls Performance Pro Nitrile Gloves Due to Defects
FDA (Devices) · 2026-10-07
Similar recalls
- HighKetamine 50mg/ml Injectable Vial Recalled for Sterility Concerns
FDA (Drugs) · 2023-02-01
- SevereKetamine 50 mg Infusion Solution Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2022-03-23
- SeverePharmakon Recalls Ketamine Syringes Due to Sterility Assurance Concerns
FDA (Drugs) · 2016-07-20
- SevereRXQ Compounding Recalls Methylprednisolone Acetate Injection Due to Sterility Concerns
FDA (Drugs) · 2017-10-25
- SeverePharmakon Recalls Ketamine Bags Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SeverePharmakon Recalls Ketamine Syringes Due to Sterility Concerns
FDA (Drugs) · 2016-07-20